 DermTech Inc NASDAQ: DMTK shares were soaring to a new high Thursday after the company unveiled a contract with Blue Cross Blue Shield of Texas for its melanoma gene express test. What Happened: La Jolla, California-based DermTech, a precision dermatology company, said it has entered into a contract with the BCBSTX for making its pigmented lesion assay, or PLA, which became available to the health insurers 6 million members in the state of Texas Feb. 1. 